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Acute lymphoblastic leukaemia (ALL) is the most common cancer of childhood. Although the overall survival of children with
ALL is nowmore than 90%, leukaemia remains one of the leading causes of death from disease. In developed countries, the overall
survival of patients with ALL has increased to more than 80%; however, those children cured fromALL still show a signiﬁcant risk
of short- and long-term complications as a consequence of their treatment. Accordingly, there is a need not only to develop new
methods of diagnosis and prognosis but also to provide patients with less toxic therapies. MicroRNAs (miRNAs) are small
ribonucleic acids (RNA), usually without coding potential, that regulate gene expression by directing their target messenger RNAs
(mRNAs) for degradation or translational suppression. In paediatric ALL, several miRNAs have been observed to be overex-
pressed or underexpressed in patient cohorts compared to healthy individuals, while numerous studies have identiﬁed speciﬁc
miRNAs that can be used as biomarkers to diagnose ALL, classify it into subgroups, and predict prognosis. Likewise, a variety of
miRNAs identify as candidate targets for treatment, although there are numerous obstacles to overcome before their clinical use in
patients. Here, we summarise the roles played by diﬀerent miRNAs in childhood leukaemia, focussing primarily on their use as
diagnostic tools and potential therapeutic targets, as well as a role in predicting treatment outcome. Finally, we discuss the
potential roles of miRNA in immunotherapy and the novel contributions made by gut miRNAs to regulation of the
host microbiome.
1. Introduction
Leukaemia, the most common paediatric cancer, accounts
for approximately one-third of malignancies diagnosed in
children below 16 years of age [1]. With a peak incidence
between 2 and 5 years of age, acute lymphoblastic leukaemia
(ALL) accounts for 85% of leukaemia in childhood [2].
*rough treatment stratiﬁcation by immunophenotype and
genotype, the incorporation of more eﬀective drug combi-
nations into treatment protocols, and improved supportive
care, overall survival of patients with ALL has increased to
more than 80% in developed countries [3–5].
Despite the dramatically improved survival rates
achieved with most treatment protocols, leukaemia in
children remains one of the leading causes of death from
disease. While the diagnostic classiﬁcations allowing for
personalized treatment and prognostic evaluation have
greatly improved, novel biomarkers for the diagnosis and
classiﬁcation of leukaemia are still required [6]. In addition,
short-term and long-term complications arising from
treatment toxicity remain a signiﬁcant risk for individuals
“cured” from their disease [7]. Hence, there is also a need for
the development of new therapies to eﬀectively treat children
with high-risk disease, as well as a better optimization of
current treatment strategies for low-risk disease.
2. MicroRNA Biology and the Role in Cancer
MicroRNAs (miRNAs) in animals are single-stranded
noncoding RNAs with a length of 19 to 25 nucleotides (nt),
usually formed from hairpin-shaped precursors. *e
canonical biogenesis of miRNAs (extensively reviewed in
Hindawi
Journal of Oncology
Volume 2019, Article ID 8941471, 14 pages
https://doi.org/10.1155/2019/8941471
[8, 9]) involves a complex process that converts the primary
miRNA transcript (pri-miRNA, often up to 1000 nt in
length) into an active mature miRNA. Brieﬂy, the pri-
miRNA transcript is processed by the Class 2 ribonuclease
III enzyme, DROSHA, into a precursor miRNA (pre-
miRNA, 60–120 nt) that bears a hairpin structure with a 2-nt
overhang at the 3′ end. *e overhang is recognised by
EXPORTIN 5 (XPO5) and the pre-miRNAs are exported to
the cytoplasm where they are processed by the endor-
ibonuclease DICER into the mature miRNA duplex (19–
25 nt). *e 3′ or 5′ of the miRNA duplex is then loaded into
the Argonaute family of proteins to form the miRNA-in-
duced silencing complex (RISC) (Figure 1). Multiple non-
canonical pathways also exist that make use of diﬀerent
combinations of DROSHA, EXPORTIN 5, and DICER [8].
For example, short-hairpin RNAs can be processed by
DROSHA into miRNA through a DICER-independent
pathway and “mitrons” can be produced from the spliced-
out introns of RNA coding genes through a DROSHA-in-
dependent process. However, originally described as not
having coding potential, more recent evidence has identiﬁed
a subset of pri-miRNA that can indeed encode small pep-
tides [10]. Such pri-miRNAs contain small open reading
frames of around 300 nt that may be transported, un-
processed, into the cytosol where they become translated
into micropeptides that can inﬂuence a variety of biological
processes. Functional studies of micropeptides in humans
are now beginning to show a signiﬁcant association with
disease and may possibly also present novel therapeutic
opportunities [10]. miRNAs function by regulating the
expression of genes usually through direct seed binding to
the 3′ untranslated regions of their target messenger RNAs
(mRNAs) and downregulate gene expression by acceleration
of mRNA degradation (Figure 1). An alternative binding
mechanism used by miRNAs involves particularly weak base
pairing in the centre of the target pairing as a consequence of
mismatched bulges in the miRNA sequence; this in turn
leads to inhibition of translation [8]. miRNA binding sites
have also occasionally been identiﬁed in the 5′ untranslated
regions and open reading frames of mRNA, although these
models are still under investigation [11]. Hence, miRNA are
an important class of gene regulator estimated to be involved
in the regulation of ∼30% of all genes and can regulate
almost every genetic pathway. Consequently, dysregulation
of miRNA expression leads to the dysregulation of down-
stream mRNA targets and may be accompanied by severe
implications to the homeostasis of cells and tissues [12].
Similar to traditional protein-coding genes, miRNA
genes can be altered by a variety of aberrations including
chromosomal ampliﬁcations, transcriptional activation,
deletion, methylation, and sequence variation. Alterations of
miRNAs have been identiﬁed in numerous diseases such as
cardiac disorders, autoimmune diseases, and cancers; in the
latter, they are highly dysregulated and can act as either
oncogenes (oncomiRs) and/or tumour suppressors. For
example, acting as an oncogene, overexpression of miR-21 in
mice accelerates development of a precursor B (pre-B) cell
malignant lymphoid-like phenotype; however, tumours
regress completely within a few days when miR-21 is
inactivated in vivo [13]. *e role of miRNA as a tumour
suppressor is illustrated by the miR-15a/16-1 cluster, which
is frequently deleted in chronic lymphocytic leukaemia
(CLL) [14]. In a knockout mouse model, induced deletion of
the cluster results in the development of indolent B-cell-
autonomous, clonal lymphoproliferative disorders that es-
sentially reiterate the spectrum of CLL-associated pheno-
types observed in humans [14]. Furthermore, the deletion of
miR-15a/16-1 accelerates the proliferation of mouse and
human B-cells by modulating the genes that control cell-
cycle progression [14]. Examples of miRNAs acting as an
oncogene in one cell type and as a tumour suppressor in
another have also been reported; miR-221 is overexpressed
in liver cancers where it targets the tumour suppressor
PTEN, thereby promoting liver tumourigenicity [15].
However, in other tumour types, for example, gastrointes-
tinal stromal tumours, miR-221 is downregulated and the
consequent downregulation of c-KIT and ETV1 (its target
oncogenes) results in the promotion of this malignancy [16].
2.1. miRNAs as General Biomarkers of Cancer. A feature of
an ideal biomarker is that it must present a unique ex-
pression proﬁle in the patient compared to healthy in-
dividuals. Biomarkers must be reliable not only for early
diagnosis, preferably before the development of full clinical
symptoms, but also for the detection of persistence of
minimal residual disease (MRD) and the recurrence of
disease after treatment. *ey must additionally have a long
half-life in clinical samples, be accessible through non-
invasive methods, and be detected through simple, accurate,
and inexpensive methodology. *erefore, miRNAs dem-
onstrate tremendous potential as biomarkers for the early
diagnosis of malignancy (and its prognosis), since they can
be reliably detected in and extracted from blood (total,
plasma, or serum) [17]. Circulating miRNAs are packaged
inside microvesicles such as exosomes [6] and their proﬁle in
patients usually reﬂects the pattern observed in their re-
spective tumour tissues, making them an attractive possi-
bility as minimally invasive and robust biomarkers [18–20].
*e ﬁrst reported blood-based circulating miRNA was miR-
21, which showed aberrant expression levels in the serum of
diﬀuse large B-cell lymphoma patients [6].
2.2. miRNA in the Diagnosis and Classiﬁcation of Paediatric
ALL. ALL and acute myeloid leukaemia (AML) can be
distinguished by a variety of morphological, immunophe-
notypic, and immunohistochemical methods; nonetheless,
few single tests are currently suﬃcient for the establishment
of diagnosis. *e current classiﬁcation of ALL is based on
cell morphology, immunophenotypic characteristics, and
cytochemical, cytogenetic, and molecular features, and can
be divided into two distinct subgroups: B-cell precursor ALL
(BCP-ALL) and T-cell ALL (T-ALL). BCP-ALL can be
further subclassiﬁed according to recurrent genetic abnor-
malities [21, 22] and Figure 2.
To address this issue, Mi and colleagues [23] performed
large-scale genome-wide miRNA expression proﬁling and
identiﬁed 27 miRNAs that are diﬀerentially expressed
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between ALL and AML. Of these, miR-128a and miR-128b
were signiﬁcantly overexpressed in ALL compared to AML,
whereas lethal (let)-7b and miR-223 were signiﬁcantly
downregulated. *eir results show that ALL can be dis-
criminated from AML with an accuracy of greater than 95%
based on the diﬀerential expression pattern of these four
miRNAs [23].
Certain miRNA proﬁles have also been shown to as-
sociate speciﬁcally with paediatric ALL [24] and reveal
distinct expression proﬁles based on the cell of origin and
cytogenetic subtype. BCP-ALL was distinguishable from
normal bone marrow (BM) and CD34+ cells by presenting a
signiﬁcantly lower expression of miR-127 and miR-143.
Similarly, T-ALL cells diﬀered extensively from normal
thymocytes with diﬀerential expression of 28 miRNAs. In
high hyperdiploid ALL, high expression of a variety of
miRNA was also observed [24]. Interestingly, except for
BCR-ABL1-positive and “B-other” ALL, all the subtypes
BCR-ABL1 t(9;22)
3%
TCF3-HLF t(17;19)
1% iAMP 21
2%MLL-r
4%
TCF3-PBX1 t(1;19)
4%
B-others
29%
ETV6-RUNX1 t(12;21)
25%
High hyperdiploidy
30%
Hypodiploidy/haploid
2%
Figure 2: Major recurrent chromosome aberrations of childhood BCP-ALL. Hyperdiploidy and the ETV6-RUNX1 translocation constitute
the major subgroups of BCP-ALL and are associated with favourable clinical outcome. *e t(1;19) and “B-Others” subgroups are associated
with intermediate risk and the remaining subgroups are deemed poor risk.
Perfect complementarity
mRNA degradation
Translational repression
Ribosome
mRNA
mRNA
miRISC 
miRISCImperfect complementarity
miRISC
Figure 1: *e functional mechanism of miRNA in posttranscriptional regulation of gene expression. miRNAs function to regulate the
expression of genes by binding to the 3′ untranslated regions of their target messenger RNAs (mRNAs). miRNAs downregulate expression
through acceleration of the degradation of mRNA (perfect complementarity) or by inhibition of its translation (imperfect
complementarity).
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display a unique miRNA signature that distinguishes each
group from all the other subtypes. A top-ten discriminative
miRNA set was proposed for each subgroup as shown in
Figure 3 [25].
Signiﬁcantly diﬀerent levels of expression of miR-100
andmiR99a have been observed in childhood ALL, with very
low levels of expression seen in patients with ALL compared
to those with AML or in healthy BM donors [26]. Con-
versely, an association between increased miR-100 levels and
the presence of t(12;21)-positive ALL suggested the possi-
bility of a t(12;21)-speciﬁc regulation of miR-100 [27]. Ex-
pression levels of two additional tumour suppressor
miRNAs, miR-326 and miR-200c, appear to be signiﬁcantly
downregulated in BM mononuclear cells of paediatric ALL
patients at diagnosis. Moreover, area under the curve (AUC)
in receiver operating characteristic curve analysis (ROC)
showed a high sensitivity and speciﬁcity for both miRNAs in
discriminating between paediatric ALL patients and healthy
individuals. *ese ﬁndings suggest that miR-326 and miR-
200c may be involved speciﬁcally in leukaemogenesis and
serve as potential reliable noninvasive diagnostic biomarkers
of paediatric ALL [28].
RT-qPCR analysis of expression levels of miR-203 and
miR-125b in peripheral blood (PB) isolated from 43 newly
diagnosed children with ALL showed the median level of
miR-125b expression to be 33-fold higher in the ALL cases
than in the healthy control group. On the contrary, the
median expression level of miR-203 was 31-fold higher in
the control group when compared to the ALL cases. While
the sensitivity of miRNA-203 was higher than that of
miRNA-125b, their combination revealed absolute sensi-
tivity, suggesting that preclinical studies targeting miRNAs
for diagnosis of ALL should be strongly encouraged [29].
Disruption of the function of miR-181a, a regulator of
normal haematopoiesis, has been associated with many
cancer types. Depending on the cellular context and on the
consequent expression of its targets, miR-181a can act as
either a tumour suppressor or an oncogene. Nabhan and
colleagues [30] investigated the expression levels of miR-
181a in 30 newly diagnosed paediatric ALL patients, com-
paring these results with 30 sex-matched normal healthy
children as the control group [30]. Serum samples of the
ALL group showed a highly signiﬁcant decrease in ex-
pression levels of miR-181a compared to those found in the
healthy children. ETV6-RUNX1, the fusion product of t(12;
21), is the most common genetic abnormality observed in
paediatric ALL and especially BCP-ALL [31, 32]. Consistent
with a study that conﬁrmed that miR-181a is able to ef-
fectively target the fusion, decrease its protein level, and
induce a signiﬁcant antileukaemic eﬀect, it was noted that
miR-181a plays a tumour suppressor role in ALL [30, 33].
Furthermore, miR-181a was identiﬁed as the most diﬀer-
entially downregulated miRNA in the PB of paediatric ALL
patients that express ETV6-RUNX1 [34].
Additional investigations were performed to evaluate the
expression levels of the nuclear protein “mothers against
decapentaplegic homolog 7” (SMAD7), a miR-181a target
pair, and transforming growth factor-b1 protein (TGF-β1),
the response of which is negatively regulated by SMAD6 and
SMAD7 [30]. Results showed that SMAD7 protein levels
were signiﬁcantly higher in ALL patients compared to the
healthy control group, whereas TGF-β1 protein was sig-
niﬁcantly lower. Of note, deregulation of TGF-β1 signalling
through SMAD7 overexpression has been previously asso-
ciated with the pathogenesis of ALL [35].With the combined
use of miR-181a and SMAD7, the sensitivity of diagnosis was
increased to 90%, whereas the combined use of miR-181a
and TGF-β1 increased sensitivity to 100%. *ese data
suggest that the diagnostic accuracy of paediatric ALL can be
improved by using a small combination of biomarkers [30].
2.3. miRNA in the Prognosis of Paediatric ALL. Paediatric
ALL is currently stratiﬁed according to diﬀerent biological
and clinical parameters with patients subsequently receiving
risk-adapted therapy. Albeit current strategies yield a very
high cure rate, there are a number of patients with ALL who
will ultimately relapse. *e classical use of both gene ex-
pression proﬁling and mRNA signatures in the clinical
setting has disadvantages and only intermediate success has
been reported. Since miRNA proﬁling is usually limited to a
small number of genes, it can potentially oﬀer fewer and
more robust signatures that have an equally strong prog-
nostic capacity [25].
Expression levels of miR-16, a gene lost in many cases of
CLL, were assessed in 93 children with ALL and results
associated to the main biological and clinical variables that
deﬁne prognosis: white blood cell (WBC) count, age at
diagnosis, cyto- and molecular-genetic proﬁle, and risk
groups. While the highest expression values of miR-16 as-
sociated with a poor prognosis, low levels associated with a
good outcome [36]. *e disease-free survival (DFS) and
overall survival (OS) were evaluated according to miR-16
expression proﬁles in the ALL group as a whole and in the
B-cell and T-cell ALL subgroups. Group analysis showed
that DFS was longest for patients with miR-16 expression
less than quartile 25 and the shortest for those patients with
miR-16 expression above quartile 75. Relapse was rarely
observed in the patients with low miR-16 levels, while the
shortest DFS was in the quartile above 75. Similarly, in the
T-ALL group, patients in the quartile above 75 presented the
shortest survival, whilst the longest survival was observed in
the quartile below 25. Statistically signiﬁcant relationships
were also obtained between low miR-16 levels and lowWBC
and good cyto- and molecular-genetic markers [36].
In addition, a multivariate analysis of miR-24 expression,
including age at diagnosis, gender, and WBC, deﬁned miR-
24 as an independent prognostic marker. Upregulation of
miR-24 was associated with a signiﬁcant shorter OS, com-
pared to those cases with low expression [37]. *ese results
strongly suggest that high miR-24 expression levels could be
used as a reliable and eﬀective biomarker of poor prognosis
ALL (Figure 4).
*e changes in miRNA expression in relapsed ALL are
the focus of several research groups and suggest that miR-
223 and miR-128b levels could be possible predictors of ALL
relapse. Nemes and colleagues [38] collected PB and BM
samples from 24 ALL patients from all phases of treatment.
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*ey determined that whilst miR-223 expression was almost
undetectable at diagnosis, the levels of expression recovered
to normal during treatment and in remission, but then
decreased again at relapse. Conversely, an extreme over-
expression of miR-128b was observed at diagnosis, which
signiﬁcantly decreased as patients entered remission where
Possible roles for miRNA in paediatric all
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Figure 4: Potential applications of miRNA as a diagnostic and prognostic tool in paediatric ALL.*e ﬁgure summarises those miRNAs that
are either upregulated or downregulated in the various subsets of ALL and their potential use as a tool for its diagnosis and prognosis.
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Figure 3: A top-ten discriminative miRNA set for the main leukaemia subgroups. *e subtypes display a unique discriminating miRNA
(except where overlap is shown) that distinguishes each subgroup from each other [25].
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normal levels of miR-128b expression for mononuclear cells
were detected. Higher miR-128b expression levels at di-
agnosis also correlated with a better prognosis, suggesting
that monitoring of miR-128b expression levels in PB could
assist in the early detection of disease relapse (Figure 4) [38].
2.4. miRNA in Treatment, Treatment Response, and
Toxicity of Paediatric ALL. Most children diagnosed with
ALL follow a standard treatment protocol as part of a risk-
adapted strategy that is typically divided into 3 main phases:
induction, consolidation, and maintenance, and a fourth
phase of CNS-directed therapy. Although in recent times the
main cytotoxic agents used in the induction phase of
treatment have not changed, they usually include combi-
nations of drugs including prednisolone (PRED), vincristine
(VCR), L-asparaginase (L-ASP), and daunorubicin (DNR).
Multidrug regimens are used in the attempt to prevent drug
resistance but all agents have undesirable late eﬀects.
Maintenance therapy, the ﬁnal and most prolonged treat-
ment in childhood ALL, involves a much less intensive
regimen than the prior chemotherapy. Lasting up to two
years, the maintenance phase has been demonstrated to
lower the risk of relapse but may itself be a cause for the
emergence of new (drug resistant) mutations.
2.5. miRNA and Multidrug Resistance. Multidrug resistance
(MDR) is a ubiquitous and severe clinical problem in the
treatment of paediatric ALL and is often mediated by
adenosine triphosphate (ATP)-binding cassette (ABC)
transporters. Various substrates, such as drug molecules, are
actively transported by ABC transporters across extracellular
and intracellular membranes, resulting in the restriction of
drug deposition and chemotherapy failure [39]. A signiﬁcant
amount of evidence now shows that miRNAs tend to impact
upon therapy response through modulation of expression
levels of a variety of proteins, including ABC transporters
[40]. Transfection of resistant HepG2 cells with miR-326
leads to enhanced sensitivity to chemotherapeutic drugs due
to the downregulation of ABC transporter ABCC144.
Furthermore, overexpression of ABCA2 and ABCA3 genes
signiﬁcantly increases the risk of MDR and relapse in
children with ALL [41]. Bioinformatics analysis shows miR-
326 to be a negative regulator of drug resistance-related
genes, particularly ABCA2 and ABCA3 [27]. Evaluation of
the expression levels of miR-326 in paediatric ALL patients
resistant to chemotherapy revealed a signiﬁcant decrease in
miR-326 expression levels in MRD+ patients compared to
the MRD- group, supporting the notion that down-
regulation of miR-326 has an adverse impact on chemo-
therapy treatment response [28]. *e downregulation of
miR-326 in children with relapsed ALL compared to the
expression levels observed at ﬁrst diagnosis, indicate that
miR-326 can be considered another prognostic marker for
relapse in paediatric ALL (Figure 4).
To identify novel prognostic and therapeutic predictors
in ALL, a genome-wide miRNA expression study was
performed on 63 newly diagnosed childhood ALL patients
[42]. *e miRNA proﬁles of the relapse/deceased cases were
compared to those in complete remission (CR), identifying
miR-335 as the most signiﬁcantly downregulated miRNA.
miR-335 gene promoter regions reveal signiﬁcant methyl-
ation patterns in relapsed patients, suggesting that miR-335
is epigenetically silenced through DNA methylation. Epi-
genetic silencing of miRNA genes is associated with clinical
outcome in infant ALL [43, 44]. Signiﬁcantly poorer 5-year
event-free survival was observed in patients with low ex-
pression levels of miR-335, and a multivariate analysis
conﬁrmed miR-335 levels at diagnosis to be an eﬀective and
independent prognostic marker in predicting treatment
outcome [42].
miR-155 is believed to play a role in inhibition of lineage
diﬀerentiation [45], holding haematopoietic stem and
progenitor cells (HSPCs) at the early stem cell stage. El-
Khazragy and colleagues [46] determined whether miR-155
expression levels correlate with clinic-pathological features
of the disease; the eﬀect of therapy on the expression levels of
miR-155 was also evaluated by RT-qPCR. BM samples of 45
children with ALL were collected at diagnosis to determine
miR-155 expression levels, and percentage of blasts post-
induction was assessed on day 15 as a measure of MRD.
Additionally, expression levels were determined after
treatment in samples taken on day 28 and results compared
with a control group of ten healthy controls. A signiﬁcant
high level of miR-155 expression was detected at diagnosis in
the ALL group, and a signiﬁcant correlation was observed
between high miR-155 levels and high blast numbers
(>25%), unfavourable cytogenetic abnormality, total WBC,
higher relapse rate, and a higher MRD after 15 days. *e
overexpression of miR-155 therefore correlates with poor
prognosis in paediatric ALL, due to a decrease in the re-
sponse to therapy and an increase in relapse. Furthermore,
miR-155 expression levels were signiﬁcantly decreased 10-
fold after therapy, again suggesting potential use as a bio-
marker of therapeutic response in childhood ALL (Figure 4)
[46].
To further determine the miRNA expression proﬁles and
miRNA patterns associated with childhood ALL relapse, a
genome-wide miRNA microarray analysis was performed
on paired diagnostic-relapse and diagnostic-CR series of
paediatric ALL cases [47]. A diﬀerential miRNA pattern was
identiﬁed between relapse and CR patients that included
miR-223 and miR-27a: both miRNAs were highly expressed
in patients during CR. Furthermore, the expression levels of
both miR-223 and miR-27a were low in diagnostic samples
of patients who subsequently relapsed during the study.
miR-223 expression at initial diagnosis is another in-
dependent and reliable predictor for OS in paediatric ALL
patients [47].
Piatopoulou and colleagues [48] examined miRNA
proﬁles at diagnosis and after induction, comparing those
levels with known prognostic features of ALL. Lower miR-
125b expression levels at diagnosis and higher levels at the
end of the induction protocol were associated with adverse
disease features. *e stronger risk for short-term relapse and
a worse OS were clearly demonstrated by survival analysis of
patients who presented with underexpressed miR-125b at
diagnosis and overexpression after induction [48]. Albeit
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miR-125b presented with a wide variability of expression at
diagnosis, lower expression levels correlated with unfav-
ourable prognostic features including high-risk age group,
high BM blast count at diagnosis and day 15 after induction,
as well as patients with a low haemoglobin concentration.
Downregulation of miR-125b is also signiﬁcantly associated
with higher risk of relapse and a poor OS, providing con-
vincing evidence that miR-125b could also be used as a
potential prognostic biomarker in paediatric ALL [49].
With the development of miRNA inhibitors and mimics,
along with antagomiRs and agomiRs, and the possible
reexpression of miRNAs by delivery of their precursors, it is
now becoming feasible to restore miRNA levels to normal, at
least in vitro. A very attractive and possible future treatment
strategy will therefore be to combine miRNA-based therapy
with conventional chemotherapy. Gefen and colleagues [50]
established that the expression of the miR-125b-2 cluster,
consisting of miR-125b, miR-99a, and let-7c, is increased in
ETV6-RUNX1+ leukaemia.*rough manipulation of ETV6-
RUNX1 gene expression and chromatin immunoprecipita-
tion, their results show that the miRNA-125b-2 cluster is not
regulated by the ETV6-RUNX1 fusion protein itself, sug-
gesting that expression of this cluster could be an in-
dependent leukaemia event. Knockdown studies of
endogenous miR-125b in the ETV6-RUNX1+ cell line Reh
increased cell sensitivity to doxorubicin and staurosporine
treatment. Furthermore, overexpression of miR-125b-2
conferred a survival advantage through the inhibition of
apoptosis and activation of caspase-3 [50]. *ese results
suggest that miR-125b-2 cluster is another potential ther-
apeutic target in paediatric ALL (Figure 5).
*e in vitro sensitivity of cells isolated from patients with
BCP-ALL following standard treatment with prednisolone
(PRED), vincristine (VCR), L-asparaginase (L-ASP), or
daunorubicin (DNR) has been studied for respective
changes in miRNA proﬁles. While only one miRNA, miR-
454, was linked to L-ASP resistance and none to prednis-
olone, resistance to VCR and DNR was characterized by a
20-fold upregulation of miR-125b, miR-99a, and miR-100.
Moreover, 39% of the patients resistant to VCR were of
ETV6-RUNX1 subtype; the ETV6-RUNX1+ patients and the
VCR-resistant cases both presented higher miR-125b ex-
pression levels. *e overexpression of miR-125b reduced the
amount of drug-induced apoptosis in pre-B-cells and in-
duced the proliferation of CD34+ cells, suggesting that the
interference of miR-125b function might provide a way to
sensitize patients to these chemotherapeutic drugs [24]. *e
potential role of miR-125b in paediatric ALL treatment has
now been studied in vivo by Bousquet and colleagues [51].
Twenty mice were transplanted with miR125b-over-
expressing foetal liver cells and of these, half succumbed to a
haematological malignancy within 12 to 29weeks post
transplantation. *e phenotypes included both BCP-ALL
and T-ALL, suggesting that miR-125b may play a role in the
diﬀerentiation process of both lymphoid lineages. *e au-
thors conclude that miR-125b, as a driver mutation or
secondary event, could also provide a promising therapeutic
target [51]. Furthermore, miR-125b overexpression was
shown to accelerate the oncogenicity of the BCR-ABL1
fusion protein, a hallmark of chronic myeloid leukaemia
(CML) but one also observed in a subset of paediatric ALL
[52]. To evaluate the clinical utility of miR-125b for patients
treated on the Berlin-Frankfurt-Mu¨nster (BFM) protocol,
BM samples of childhood ALL patients were obtained at
diagnosis and day 33 and compared to healthy controls.
Whilst miR-125b expression levels were downregulated at
diagnosis, a signiﬁcant overexpression (between 2- and 5-
fold) was observed on day 33 [48]. To explore a role for miR-
125b, miR-99a, and miR-100 in therapy resistance, Reh cells
were treated with VCR for 3 days [53]. *e baseline ex-
pression levels of these 3 miRNAs in Reh cells were in the
range of levels observed in the leukaemic cells of children
with ETV6-RUNX1+ALL. Results showed that miR-125b, in
combination with miR-99a or miR-100, induced resistance
to VCR, whereas the same eﬀect was not observed for each of
the miRNAs individually. After combined overexpression of
miR-125b/miR-100, miR-125b/miR-99a, or miR-125b/miR-
99a/miR-100, the fold change in VCR resistance did not
diﬀer. *e mature sequences of miR-99a and miR-100 diﬀer
only by one nucleotide and consequently have considerable
overlap in the list of their predicted target genes. *e rate of
apoptosis and cell-cycle distribution in the absence of VCR
did not vary between Reh cells expressingmiR-125b together
with miR-99a and/or miR-100, compared to those cells
expressing miR-125b in combination with a scrambled
miRNA control. *ese results suggest that for the devel-
opment of VCR resistance, the combined overexpression of
miR-125b, miR-100, and/or miR-99a may provide a speciﬁc
trigger. Whether the target genes directly regulated by these
miRNAs and subsequent eﬀected pathways could provide a
way in which VCR resistance in ETV6-RUNX1+ ALL could
be modulated remains to be seen [53].
Glucocorticoids (GCs) are also widely used in the clinical
treatment of paediatric ALL; the interindividual diﬀerences
in GC therapy response, however, compromise their clinical
application. Additionally, GC resistance is one of the major
contributing factors of poor outcome in paediatric ALL.
Recent studies have shown that miRNAs play a crucial role
in GC sensitivity and may provide potential strategies to
overcome GC resistance [54]. In a genome-wide miRNA
analysis of paediatric ALL patients, a reduced miR-335
expression was identiﬁed as the most signiﬁcant miRNA
abnormality associated with poor outcome [42]. Over-
expression of miR-335 signiﬁcantly sensitized the ALL cells
to PRED, across a range of concentrations, indicating that
ectopic expression of miR-335 can confer an enhanced
sensitivity. Since no enhancement of cell death was observed
in cell lines overexpressing miR-335 when treated with other
chemotherapy drugs, it was proposed that miR-335
downregulation could decrease the susceptibility of ALL
cells to PRED treatment. To determine the functional role of
miR-335 in PRED resistance, investigation of downstream
pathways revealed that a low level of miR-335 results in
higher MAPK1-mediated survival. Moreover, MEK/ERK
inhibitor treatment enhanced PRED-induced cell death
suggesting that reintroducing synthetic miR-335 and
overriding MAPK1 activity and MEK/ERK pathway in-
hibition could provide a basis for the development of further
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therapeutic strategies to overcome PRED resistance and so
improve treatment outcome in ALL patients [42].
Clinical studies indicate that miR-210 is diﬀerentially
expressed in several types of cancer. To establish its eﬀect on
treatment outcome in leukaemia, intracellular miR-210
levels were altered by transfecting two diﬀerent paediatric
ALL cell lines (ETV6-RUNX1+ Reh andMLL-AF4+ RS4;11)
with an agomiR and antagomiR to miR-210 [55]. Twenty-
four hours after transfection, both cell lines were treated for
48 hours individually with the four common therapeutic
drugs (dexamethasone [DEX], VCR, DNR, and L-ASP) or in
four drug combinations. *e miR-210 agomiR produced an
approximate 30-fold increase and antagomiR an 80% de-
crease, respectively, compared to the negative controls. In
Reh cells, the half maximal inhibitory concentrations
(IC50s) of DNR, DEX, and L-ASP were signiﬁcantly de-
creased (agomiR) or increased (antagomiR) compared to
those cells transfected with the negative control mimics.
Similarly, in RS4, 11 cells, the IC50s of DNR, DEX, and VCR
(but not L-ASP) were decreased and increased by the miR-
210 agomiR and antagomiR, respectively. Based on these
results, the use of agomiRs or antagomiRs of miRNAs could
be a feasible alternative to overcome resistance to chemo-
therapy. It was, however, noted that safe and eﬀective de-
livery of synthetic miRNAs to leukaemia cells still remains a
great challenge [55]. As discussed later, it will also be
paramount to study the oﬀ-target eﬀects of using particular
miRNA as a therapeutic target, either alone or with che-
motherapy, since both treatments can regulate the expres-
sion of other critical miRNA.
Although quite rare in children, ALL patients that
harbour the p190 variant of the BCR-ABL1 (Ph+) fusion
gene are treated with tyrosine-kinase inhibitors (TKI) such
as imatinib, but the prognosis of these patients remains
suboptimal. ABL1 is a direct target of miR-203 and in
malignancies expressing either ABL1 alone or BCR-ABL1,
miR-203 is silenced through genetic and epigenetic mech-
anisms. Restoration of the expression of miR-203 reduces
levels of ABL1 and BCR-ABL1 and inhibits cell proliferation
[56, 57]. To determine whether the inhibition of BCR-ABL1
by miR-203 is suﬃcient to overcome resistance to TKI, cells
expressing BCR-ABL1, as well as cells overexpressing both
BCR-ABL1 and miR-203 together, were treated with ima-
tinib and cell viability determined. At all drug doses, the
BCR-ABL1+ cells without miR-203 overexpression retained
higher viability, suggesting that the sensitivity of BCR-
ABL1+ cells to imatinib could be increased with the res-
toration of miR-203 [58].
2.6. miRNAs as Tools for Immunotherapy. In the main,
studies of miRNA biology have focused on their role as
Possible roles for miRNA in treatment, treatment response and
toxicity of paediatric all
ETV6-RUNX1 + cells with downregulated miR125b
show increased sensitivity to doxorubicin and staurosporine↓miR-223
Overexpression acts as a secondary event in development of 
leukaemia, making a promising therapeutic target
A combination of miR-125 expression levels and established 
prognostic markers, significantly improves stratification of 
patients for poor response to BFM protocol, compared to the 
study of disease markers alone
Sensitize ALL cells to the glucorcorticoid prednisolone.
Possible therapeutic strategy to overcome prednisolone 
resistance, reintroduce synthetic miR-335 in patients with 
low expression levels of miR-335
↑miR-1208
↑miR-1206
↑miR-125b
miR-125b
↑miR-335
Enhances sensitivity of leukaemia cells to common 
therapeutic drugs and decreases viability.
Possible therapeutic strategy to introduce agomir of miR-210
↑miR-210
Increasing expression levels of miR-203 in BCR-ABL1+
leukaemia increases the sensitivity of cells to imatinib↑miR-203
Upregulated in patients with acute anthracyclin-induced 
cardiotoxicity. A predictive biomarker of ‘at risk’ patients?
↑miR-29b
↑miR-499
Sensitize ALL cells to the glucorcorticoid prednisolone.
Possible therapeutic strategy to overcome prednisolone 
resistance, reintroduce synthetic miR-335 in patients with 
low expression levels of miR-335?
Figure 5: Potential applications of miRNAs as biomarkers of treatment response and toxicity in paediatric ALL. *e ﬁgure summarises
those miRNAs that are either upregulated or downregulated in the various subsets of ALL during therapy. *eir potential use as a tool for
treatment or marking treatment response is discussed in the text.
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either oncogenes or tumour suppressors; however, recent
advances in our understanding of the immune system
suggest that miRNA also play an important role in immune
regulation and can therefore act as both agents and targets of
immunotherapy. Immune checkpoints play a signiﬁcant role
in cancer therapy; control of checkpoint receptors through
miRNA may be through direct target of checkpoint genes or
via other proteins that themselves are regulated by miRNA.
Checkpoint inhibitors are able to block the proteins that
prevent the immune system from attacking cancer cells. As
discussed above, in the context of being able to restore
normal miRNA levels, miRNA mimetics can be used to
restore the expression of the various downregulated
miRNAs that target immune checkpoint mRNAs and
consequently can serve to reduce the levels of checkpoint
proteins. A comprehensive role for miRNA in B-cell biology
is rapidly being documented, but one important established
mark is in the acceleration of bone marrow diﬀerentiation.
Numerous miRNA appear expressed in a stage or disease-
speciﬁc fashion in both early and late B-cells, suggesting
functional and/or pathologic speciﬁcity. Koralov and col-
leagues [59] have shown that a deﬁciency in Dicer results in a
signiﬁcant defect in B-cell diﬀerentiation at the pro-B to pre-
B-cell stage, and a number of miRNAs have been identiﬁed
that are dynamically controlled during early B-cell lineage
speciﬁcation [60]. For example, the expression level of miR-
155 is raised in murine BCP-ALL, suggesting that miR-155
can cause arrest and accumulation of pre-B-cells [61].
Programmed cell death protein 1 (PD1) is a cell surface
receptor checkpoint protein expressed on pro-B-cells (and
T-cells) that down regulates the immune response [62]. *e
antitumor activity of PD-1 immune checkpoint blockade has
been established in clinical trials [63] where solid tumour
regression was observed. Targeting PD-1, or the genes of its
ligands (PD-L1 and PD-L2), has since identiﬁed a number of
miRNAs (including miR-34a and miR-424) that can activate
anticancer immunity, initiate apoptosis, and reverse che-
moresistance by blocking the PD-1 immune checkpoint
[64, 65]. In addition, miR-142-5p was found to down-
regulate the expression of PD-L1 by directly binding to the 3′
UTR of PD-L1 mRNA [66]. *e let-7 family of miRNA is
generally considered to be a good biomarker for the di-
agnosis and prognosis of ALL, but have also been shown to
be involved in metabolic control and the normal immune
response [67]. As discussed later, one exciting prospect for
future treatment strategies is the knowledge that the gut
microbiome in patients for whom PD-1 blockers work well
diﬀers considerably from those patients in whom they fail
[68].
Chimeric antigen receptor-T (CAR-T) cell therapies
have recently begun to show dramatic success in clinical
trials that treat patients with BCP-ALL [69]. Analysis of the
transcriptome proﬁles in patients with B-ALL before and
after CAR-T therapy, in combination with miRNA-seq,
revealed that many miRNAs (including let-7 family mem-
bers) are involved in the immune process and could also
regulate the crosstalk between the transcription factors and
histone proteins involved in the response to CAR-T therapy
[70]. For example, within an elegant regulatory network, the
authors showed that FOS, JUN, and CEBP regulate the
expression of histone genes HIST1H4A and HIST2H4A,
which were targeted by miR-148a-3p. In addition, 15
upregulated and 7 downregulated miRNAs were also
identiﬁed in patients in remission that may now become
additional biomarkers of prognosis.
2.7. miRNA and Late Eﬀects of Treatment. Anthracyclines
such as doxorubicin are also used widely in the treatment of
paediatric leukaemia. Anthracycline (AC)-related car-
diotoxicity is one of the most signiﬁcant long-term threats to
survivors of cancer, with cardiac events being the most
common cause of death in this population. It has been
estimated that the prevalence of cardiomyopathy in 50-year-
old survivors of childhood cancer exposed to cardiotoxic
chemotherapy is 21% [71]. AC-induced cardiomyopathy is
progressive, with no deﬁnitive treatment, and currently
methods to detect cardiac injury early in the course of its
progression are lacking. *e speciﬁcity and sensitivity of
detection that has been established by miRNAs in various
cardiovascular disease states indicates a potential role for
miRNAs in early detection of cardiotoxicity. To identify AC-
induced alterations in the expression of plasma miRNA and
to correlate these changes to known markers of cardiac
injury, a prospective cohort study was performed on chil-
dren receiving AC chemotherapy [71]. A key ﬁnding was
that the overall dysregulation of a panel of plasma miRNAs
(with cardiac relevance) was greater following AC therapy
compared to the control group. Furthermore, plasma miR-
29b andmiR-499 were particularly upregulated in patients as
demonstrated by increased troponin concentrations post-
AC. *e post-AC expression levels of miR-29b and miR-499
correlate signiﬁcantly with cumulative AC dose, a known
predictor of cardiotoxicity risk. Further studies are required
to determine the mechanistic role of these miRNAs in AC-
induced cardiac injury but miR-29b and miR-499 could be
useful for identifying patients at high risk for developing
AC-induced cardiomyopathy and subsequently in the early
detection of cardiomyocyte injury [71].
Methotrexate (MTX), widely used in the consolidation
phase of treatment for childhood ALL, is also considered to
be a main cause of the hepatotoxicity observed in two-thirds
of patients. Many genes involved in normal liver-speciﬁc
signalling pathways are tightly controlled by miRNAs and
shown to be open to modulation by variations in miRNA
gene sequence. A signiﬁcant association between high levels
of transaminase toxicity during MTX treatment in the
consolidation phase (but not induction phase) and the
presence of a single nucleotide variation (rs264881) that
eﬀects stability in the pre-miRNA of miR-1208 has been
identiﬁed [72]. As expected, targets of miR-1208 include
genes of the MTX pharmacodynamic and pharmacokinetic
pathways; among them, dihydrofolate reductase (DHFR) is a
principal target of MTX. *is ﬁnding suggests that a higher
expression of miR-1208 could perhaps moderate the adverse
toxic eﬀects of MTX that arise through inhibition of DHFR
[72]. Other similar miRNA-related SNPs have shown their
worth as tools for the prediction of treatment-related
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toxicity; for example, more than one study has conﬁrmed the
association between the rs2114358 variant in miR-1206 and
MTX-induced oral mucositis, which occurs in 20% of MTX-
treated paediatric ALL [73, 74]. *e search continues to
discover other beneﬁcial miRNA with nucleotide sequence
variations that may also become predictors of toxicity. To
date, no miRNA drug candidates have entered into phase 3
clinical trials for the treatment of patients with ALL, and the
long-term eﬀects of such treatments remain to be evaluated.
However, oﬀ-target eﬀects of miRNA antagonists and
mimics may trigger both neurotoxicity and immunotoxicity
[75].
2.8. Future Perspectives: Gut miRNA. Implicated in host
metabolism, immunity, and disease, the gut microbiota are a
complex and diverse population of commensal bacteria, the
composition of which in children is inﬂuenced by genetics,
birth route, diet, and disease [76]. *ere is a signiﬁcant
interpersonal and interspecial variation between the gut
microbiota of individuals, characterized by a balance and
composition that is usually unique to and beneﬁcial to the
host. Disruption of this balance results in disease suscep-
tibility; therefore, it is important to characterize the bi-
ological mechanisms through which the host can maintain
the gut microbiota composition and to understand how this
relationship is aﬀected during pathological changes.
Recent studies have identiﬁed host gut or faecal miRNAs
as a readily detectable and quantiﬁable normal component
of human faeces [76]. Whilst the functional role of miRNAs
in the communication between the host andmicrobes is only
just beginning to be understood, recent ﬁndings indicate
that miRNAs produced by the host intestinal epithelial cells
can aﬀect bacterial growth within the gut and hence par-
ticipate in shaping the gut microbiota. Indeed, miRNA can
enter bacteria and regulate bacterial gene expression and
growth [76]. Furthermore, it has been shown that host
miRNA expression levels can become dysregulated in the
presence of a disturbed gut microbiota (for example, after
chemotherapy or antibiotics) and that expression of host
miRNA can in turn be inﬂuenced by the gut microbiota
[77, 78]. A link between the gut microbiota and miRNA
expression has been well studied in colorectal cancer (CRC)
and conﬁrms that certain miRNAs can mediate an in-
teraction between the host and the microbiome. Novel
mechanisms have also been implicated whereby miRNA
may provide a possible target for therapeutic strategies in
CRC patients [79]. Furthermore, numerous studies have
investigated how faecal miRNAs can be exploited as po-
tential noninvasive diagnostic and prognostic biomarkers.
*e faecal-based miR-20a and miR-221 are only two of the
several faecal miRNAs that have so far been identiﬁed as
promising diagnostic biomarkers of CRC [80, 81]. Adult
survivors of childhood BCP-ALL often have health problems
that continue for many years after the end of treatment, and
chemotherapeutic agents and antibiotics clearly have an
adverse eﬀect on the gut and associated tissues. Reduced
microbial diversity evidently exists in survivors of BCP-ALL
and may be accompanied by an increase in biomarkers of
inﬂammation (such as IL-6) and the activation of T-cells
[82]. High levels of IL-6 are thought to play a role in ex-
pression of let-7a [83]. In accord with the “Greaves hy-
pothesis” of an infectious origin for BCP-ALL [82], Bu¨rgler
and Nadal [84] suggest that memory T-helper (*) cells may
be attracted by preleukaemic B-cells and can then be acti-
vated through presentation of antigens. BCP-ALL cells can
also respond to * cell cytokines [84]. Correspondingly,
miRNA have been shown to play a role in the regulation of
cytokine genes and to be strongly regulated themselves
during inﬂammation. Indeed, many downstream compo-
nents of TGF-β signalling, eg, SMAD genes, contain miRNA
binding sites and SMADS can induce positive or negative
regulation of miRNA transcription [85]. SMAD3 has been
shown to play a role in dysregulation of the TGF-β pathway
in ETV6-RUNX1+ preleukaemia [86] and may contribute to
both the persistence or maintenance of covert preleukaemic
clones in healthy children and enhance their competitive
positive selection in an inﬂammatory context. De-
termination of the “preleukaemic” gut miRNA proﬁle in the
faeces of healthy children with ETV6-RUNX1 fusion remains
an important goal.
*ere is now substantial evidence that the normal gut
microbiome is acquired very early in life, particularly in the
ﬁrst year, and can be modiﬁed for up to three years, where it
ﬁnally stabilises [87, 88]. *e evidence that microbiome
status is a key risk variable in ALL is indirect and based upon
indirect measures made through epidemiological studies
[89]. However, the important acquisition of the microbiome
in early life involves the same features implicated in risk of
BCP-ALL: birth route, breastfeeding, and social contacts.
Microbial exposures earlier in life appear protective but, in
their absence, later infections may trigger the critical sec-
ondary mutations and gene deletions necessary for overt
leukaemia. Moreover, BCP-ALL has a worldwide incidence
that tracks with socioeconomic development and there is
now considerable evidence to indicate that children in de-
veloped countries have a gut microbiome that is lower in
diversity from those living in more basic environments [89].
Currently, several groups are performing studies to de-
termine the expression levels and functional role of faecal
miRNA and gut bacteria in childhood leukaemia. In-
formation obtained will provide insight into the patho-
genesis of childhood ALL and intrinsically particular
miRNA may be considered as tools for prevention of certain
subtypes of ALL. It is currently unknown, in the context of
ALL, which bacteria or viral species are most relevant to
neonatal immune priming and which, if any, might have the
capacity to prevent, or provide the infection trigger, for overt
ALL to develop from a clinically silent preleukaemia. One
way to assess whether bacterial species and relevant host
miRNA are critical to either prevention or promotion of
ALL will be to assess in young children the impact of an-
tibiotics on erosion of the beneﬁcial gut bacterial micro-
biome. Faecal miRNA transplantation has already been
shown to be able to restore the gut microbiota [76] and will
undoubtedly provide future therapeutic options. In humans,
these biomarkers may help to provide candidate species for
intervention with prebiotics and probiotics.
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3. Conclusions
miRNAs, a class of noncoding RNAs, target mRNAs and
regulate gene expression posttranscriptionally. Furthermore,
miRNAs are diﬀerentially expressed in distinct stages of
lymphopoiesis and inﬂuence the maturation process of
lymphoid precursors. *e aberrant miRNA signatures ob-
served in ALL can be used to deﬁne biomarkers for di-
agnosis, classiﬁcation, and prognosis of this disease.
Circulating miRNAs can be detected with the use of sensitive
and easily applicable methods such as RT-qPCR, allowing
for easy detection and a minimally invasive approach for
diagnosis of ALL. Indeed studies are currently being per-
formed to establish a highly sensitive and speciﬁc set of 2-3
miRNAs that will allow for accurate diagnosis and classi-
ﬁcation of this haematological malignancy [90]. Speciﬁc
proﬁles of miRNA expression have also been described for
commonly used drugs, uncovering miRNAs that are asso-
ciated with treatment response. Changes in expression levels
of several miRNAs have been shown to play functional roles
both in leukaemogenesis and in drug resistance; reversal of
such expression proﬁles could improve drug sensitivity and
subsequently give rise to better clinical outcomes [29, 91]. A
number of miRNA have consistently been reported to be
dysregulated in paediatric ALL, incorporating diﬀerent
cellular or molecular subgroups [27, 92]. Whilst the utili-
zation of miRNA as diagnostic and predictive biomarkers is
promising, there are still a few diﬃculties that need to be
addressed [91]. *ere are inconsistencies in the methods
being used for miRNA detection between diﬀerent studies
and comparable studies may share limited similarity within
mRNA proﬁles when diﬀerent stages of normal and aberrant
cells are compared. *ere is therefore a need for uniformity
in the collection of cells in both the experimental and control
groups, as well as standardisation in the methods of de-
tection [91, 93]. Currently, there are limited strategies to
interrupt miRNA function; whilst the transfection of
miRNA mimics or miRNA inhibitors in vitro allow for the
increase or decrease of speciﬁc miRNA expression levels,
safety concerns and degradation eﬀects still limit their ef-
ﬁcacy in vivo. *e need for systemic delivery of miRNA as a
therapeutic agent in the treatment of ALL itself raises the
issue of unforeseen late eﬀects of treatment.
Finally, albeit that survival of children with ALL has
dramatically improved, there is still a need for deﬁning novel
sensitive, eﬃcient, and reproducible biomarkers such as
miRNA that can be used for early diagnosis, classiﬁcation,
prediction of treatment response, and ultimately perhaps
even its prevention.
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